Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimenrelated toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Nonrelapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimenrelated toxicity is frequent and recurrent malignancy remains the major obstacle.
The incidence of therapy-related leukemia and MDS is rising. 1,2 First described after treatment with alkylating agents for lymphoma and more recently after treatment with epipodophyllotoxins or other DNA topoisomerase inhibitors, the prognosis for patients with these disorders is poor, with a median survival of 4 months 3, 4 although case reports of spontaneous remissions exist. 5 The largest series of induction chemotherapy in patients with therapy-related leukemia and myelodysplastic syndrome found only a 34% complete remission rate in 148 patients. 6 Bone marrow transplantation can be curative, with recent case series reporting disease-free survival estimates of 7.8-27.5%. [7] [8] [9] [10] [11] [12] [13] Interpretation of the published data is difficult as patients with AML following a myelodysplastic phase are often described as secondary AML regardless of whether the patient received prior chemotherapy. Ander-son et al 7 have proposed that routine use of pretransplant cytoreductive therapy is not warranted although their series included only 17 patients with therapy-related AML. Additionally, the majority of patients reported have been adults.
We report the largest pediatric transplant series to date with detailed information regarding regimen-related toxicity and outcome.
Patients and methods

Patient population
Eleven patients with therapy-related leukemia or MDS received an allogeneic bone marrow transplant at The Children's Hospital of Philadelphia between March 1994 and September 1997. Five of these patients had received their initial chemotherapy at referring institutions. Clinical characteristics are shown in Table 1 . The median patient age at the time of diagnosis of initial disease was 8 years (range 0.9-15). The initial diagnosis was a solid tumor in all but one patient. Patients 8 and 11 had subsequently undergone salvage therapy for relapse of their bone tumors. Patient 10 had a rhabdomyosarcoma that was refractory to original therapy but responded to aggressive treatment with alkylating agents and brachytherapy.
Ten patients had received prior irradiation with six of the fields involving the chest and/or abdomen. One patient had undergone an autologous BMT with TBI for stage IV neuroblastoma 28 months prior to her subsequent matched unrelated donor BMT for MDS. All patients had received prior treatment with a combination of alkylating agents and DNA topoisomerase inhibitors except patient 5, who had received alkylating agents and irradiation. Patients 4 and 5 have cancer predisposition syndromes, namely neurofibromatosis and Turcot's syndrome, respectively. The latter diagnosis was made after BMT when the patient's third cancer was diagnosed and the patient's sibling developed a brainstem glioma.
The median time to secondary acute leukemia or MDS was 33 months (range 17-112). Diagnoses of subsequent leukemia or MDS were classified according to FAB criteria. 14, 15 Cytogenetics were available in all 11 cases; abnormalities were found in nine. Abnormalities involved chromosome band 11q23 in four cases and complete or partial monosomy of chromosomes 5 or 7 in four other cases. The four patients with RAEB did not receive chemotherapy for their myelodysplastic syndrome prior to transplantation. None of the patients with MDS had circulating blasts at the time of transplant. All patients with acute leukemia were in remission at the time of transplantation. The two patients with secondary acute lymphoblastic leukemia had received a standard four-drug induction with vincristine, prednisone, l-asparaginase and daunomycin. Four of the five AML patients received high-dose cytarabine followed by l-asparaginase 16 while the final patient was successfully induced with infusional daunomycin and cytarabine. 17 
Treatment
Required pre-transplant organ function criteria included a shortening fraction of у27%, pulmonary function testing Ͼ60% of predicted, a creatinine clearance of Ͼ65 ml/min/1.73 m 2 and the absence of occult untreated infection. All patients met these criteria; however, six patients had a history of significant pre-transplant events. Patients 3 and 6 had prior episodes of clinical congestive heart failure requiring digitalization or afterload reduction. Patient 7 had a prior episode of veno-occlusive disease (VOD) during chemotherapy. Patients 4 and 6 had single kidneys (after nephrectomies for Wilm's tumor and neuroblastoma, respectively). Patient 9 had required dialysis during induction for his primary malignancy (ALL). Additionally, patients 7 and 8 required transfusion with HLA-matched platelets prior to BMT.
The median time from diagnosis of secondary leukemia or MDS to BMT was 3 months (range 1-12). Seven patients received marrow from unrelated donors that in all but one case was phenotypically identical at the A and B loci by serologic testing and at the DR and DQ region by high resolution oligonucleotide typing. The remaining four patients received grafts from HLA-identical siblings. Preparative regimens are shown in Table 2 and included busulfan 4 mg/kg p.o. in divided doses daily for 4 days and cyclophosphamide 50 mg/kg i.v. once daily for 4 days in nine patients. Four of these patients also received anti-thymocyte globulin (ATG). One patient received busulfan 4 mg/kg p.o. in divided doses daily for 4 days followed by etoposide 40 mg/kg i.v. once and cyclophosphamide 60 mg/kg i.v. once daily for 2 days. Busulfan levels were not obtained. One patient who received a T cell-depleted graft was conditioned with cyclophosphamide 45 mg/kg i.v. once daily for 2 days, cytosine arabinoside 3 g/m 2 twice daily for six doses and 1320 cGy of TBI as previously described. 18 GVHD prophylaxis included cyclosporine and methotrexate (15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11) for the six patients who received non-T celldepleted unrelated donor grafts. GVHD prophylaxis for the remainder of the patients was cyclosporine alone. Colonystimulating factors were not administered. No prophylaxis for VOD was given. All patients were nursed in HEPAfiltered rooms and received low bacteria diets and gut decontamination. Seven recipient/donor pairs were CMV negative. Informed consent was obtained from each patient and/or guardian. GVHD was graded according to standard criteria. 19 
Statistical analysis
Regimen-related toxicity was scored according to the grading system proposed by Bearman et al. 20 Comparison of the incidence of grade II, III or IV in our series vs that of Bearman et al was done by 2 analysis. Disease-free survival measured from the time of transplantation was analyzed according to the method of Kaplan and Meier. 21 All P values are two-sided.
Results
All patients engrafted with a median time to an ANC Ͼ500/l of 19 days (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and to an ANC Ͼ1000/l of 22 days (range [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The median time to a platelet count of Ͼ20 000/l was 31 days (range 18-69) in the nine patients who achieved platelet independence. Other than stomatitis and according to the scale published by Bearman. L = limited; E = extensive; URD = unrelated donor; Bu = busulfan; Cy = cyclophosphamide; S = skin; L = liver; G = gastrointestinal; NA = not assessable.
Patients 9 and 11 died of VOD and GVHD, respectively, prior to achieving platelet independence. The median times to platelets of Ͼ50 000/l and Ͼ100 000/l were 33 and 64 days, respectively (ranges 18-90 and 18-104).
All patients were evaluable for acute GVHD. Six patients developed grade II and two patients grade III skin GVHD. Patient 11 died of gastrointestinal (GI) GVHD as described above. Two others developed grade III GVHD involving the liver and/or GI tract but responded to treatment with steroids. Extensive chronic GVHD developed in four of eight patients who survived 100 days post transplant.
All patients experienced grade II stomatitis. All but two patients developed other organ toxicity as shown in Table  2 . Six of 11 of our patients developed grade III or IV toxicity in at least one organ compared with 30 of 195 of the patients in Bearman's series (P = 0.03).
Transplant events often recapitulated events during prior therapy. For example, patient 9 who had required dialysis during induction therapy for his original leukemia again required dialysis during BMT despite a creatinine clearance of 89 ml/min/1.73 m 2 immediately pre-transplant. Likewise, patient 1 with a prior history of VOD during chemotherapy again developed VOD during transplant. This patient and two others with significant VOD who did not require dialysis were treated with recombinant tissue plasminogen activator and infusions of anti-thrombin III concentrate; all improved. The overall transplant-related mortality was 27% (three of 11) as in addition to the two patients described above, another died of Pneumocystis carinii pneumonia (PCP) 6 months post transplant while receiving pentamidine prophylaxis.
Five patients developed recurrent malignancy. Patient 8 died from recurrence of osteosarcoma. Patients 2, 4 and 10 died of recurrent leukemia or MDS. Patient 5 has been shown to have Turcot's syndrome and developed third and fourth malignancies (duodenal carcinoma and an anaplastic astrocytoma). Three patients survive disease free at 14, 31 and 43 months post transplant. The 2 year actuarial diseasefree survival is 24% (95% confidence interval = 5-53%) as shown in Figure 1 . Two survivors have chronic extensive GVHD and the third has a creatinine of 3.2 mg/dl presumably due to radiation nephritis.
Discussion
It has been suggested that patients with therapy-related AML who undergo allogeneic BMT in first complete remission and are conditioned with busulfan and cyclophosphamide have a disease-free survival rate similar to patients with de novo AML. 22 9 reported a 27% 5 year DFS in 11 patients (including two pediatric patients) with therapy-related MDS or AML. The largest series to date found a 27.5% DFS at a median follow-up of 28 months in 35 patients with therapyrelated MDS and AML. 10 Another large study by De Witte et al 11 did not separate the outcome of patients with therapy-related leukemia from those with 'secondary AML' following a myelodysplastic phase without prior radiation or chemotherapy.
The largest pediatric series to date of the outcome of treatment for therapy-related AML by Pui et al 13 reported three survivors of 15 pediatric allogeneic transplant recipients for epipodophyllotoxin-induced AML. Details of the cause of death in the other 12 patients were not provided.
The majority of prior reports of patients transplanted for therapy-related leukemia or MDS have been in those previously treated for Hodgkin's disease [7] [8] [9] 11, 23, 24 or acute lymphoblastic leukemia. 12 The majority of patients in this study received prior therapy for a solid tumor. Le Beau et al 25 commented that the striking increase in the number of patients in their series with therapy-related AML after a primary solid tumor was due to the recent success of solid tumor therapeutic trials. Present pediatric trials of solid tumors often include both DNA topoisomerase inhibitors and alkylating agents.
Therapy-related acute lymphoblastic leukemia, seen in two of the 11 patients, is less common than therapy-related AML or MDS. Either B or T cell lineage ALL can be seen and may demonstrate translocations or deletions of chromosome 11q23. 26 The translocation patterns are similar in therapy-related and de novo cases.
These patients present special challenges during transplantation. Prior radiation therapy may preclude TBI. This in turn narrows the acceptable donor pool as present methods of T cell depletion require TBI containing preparative regimens. Prior therapy with anthracyclines or radiation may also potentiate effects of conditioning. Longmore et al 9 first reported an increased incidence of severe or moderately severe regimen-related toxicity in patients transplanted for secondary AML and MDS. Our study confirms their findings in the pediatric population who might have been expected to tolerate the transplantation procedure better. Although all patients met institutional pre-transplant organ function criteria, their true organ function reserve may have been overestimated. Of note, the significant episodes of pretransplant organ dysfunction (such as VOD) occurred during therapy for the primary malignancy and not during induction chemotherapy for the therapy-related leukemia in this series of patients. Thus, even if induction chemotherapy is not given pretransplant, significant regimen-related toxicity may be expected.
Another obstacle to cure is relapse of either the secondary leukemia or the primary cancer. Some authors have questioned whether non-TBI containing preparative regimens are associated with inadequate tumor ablation and a higher risk of relapse. Although patient numbers are too small to draw firm conclusions, it appears that patients with therapy-related AML conditioned with busulfan and cyclophosphamide have a higher risk of relapse than do patients with de novo AML conditioned with the same agents. 7 Thus, it has been concluded that therapy-related AML is biologically more aggressive and/or more resistant to treatment than spontaneous AML. Others report favorable subgroups within the secondary leukemia and MDS patients including patients with t (8;21) and inv (16) . 27 None of our patients exhibited these karyotypes.
An unsuspected cancer predisposition syndrome may be associated with development of additional malignancies as was true for patient 5. Additionally, given that malignancy is a recognized complication of transplantation, 28, 29 it is reasonable to expect that survivors of BMT for therapyrelated leukemia will be at significant risk of developing third malignancies even in the absence of a familial cancer predisposition. Although no such reports presently exist, the published number of survivors of BMT for therapyrelated leukemia and MDS total less than 40 in number and follow-up time is short.
As the number of patients with therapy-related leukemia and MDS is increasing, new treatment strategies are needed. Our series demonstrates the present difficulties of transplant regimen-related morbidity as well as mortality due to recurrent malignancy post BMT.
